Physician Interpretation of Information About Prescription Drugs in Scientific Publications vs. Promotional Pieces

Forms and Documents

Forms and supporting documents for this ICR

Document	Type	Status	Availability
Support Statement Part B Physician Interpretation Study 2019.doc	Supporting Statement B	Uploaded 2019-07-03	Available
Supporting Statement Part A Physician Interpretation Study 2019.docx	Supporting Statement A	Uploaded 2019-07-03	Available

IC Document Collections

Information collection document groups

IC ID	Collection	Type	Status	Form
236802	Completes, Main Study	Other-Survey Instrument	New
236801	Completes, Pretest	Other-Survey Instrument	New
236800	Main Study Screener	Other-Screener	New
236799	Pretest Screener	Other-Screener	New

ICR Details

OMB Control No: 0910-0875	ICR Reference No: 201907-0910-005
Status: Historical Active	Previous ICR Reference No:
Agency/Subagency: HHS/FDA	Agency Tracking No: CDER
Title: Physician Interpretation of Information About Prescription Drugs in Scientific Publications vs. Promotional Pieces
Type of Information Collection: New collection (Request for a new OMB Control Number)	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 09/09/2019
	Date Received in OIRA: 08/08/2019
Terms of Clearance: Any changes made as a result of the pre-test will need to be submitted and approved prior to fielding the main study.

table that charts list comparision

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	09/30/2021	36 Months From Approved
Responses	1,621	0	0
Time Burden (Hours)	267	0	0
Cost Burden (Dollars)	0	0	0

---

Abstract: This study will examine how physician perception of professional prescription drug communications is influenced by variations in information context, methodologic rigor of the underlying clinical study, and time pressure. We plan to conduct one pretest (N = 158) and one main study (N = 566) not longer than 20 minutes, administered via Internet panel. Using a description of a trial for a fictitious prescription drug, we will vary the context of the information, the methodologic rigor of the information, and the amount of time available to read the information. Participants will view the information and then answer questions about the drug information.

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	83 FR 52490	10/17/2018
30-day Notice:	Federal Register Citation:	Citation Date:
	84 FR 34897	07/19/2019
Did the Agency receive public comments on this ICR? Yes

---

Number of Information Collection (IC) in this ICR: 4

table that charts list of burden

IC Title	Form No.	Form Name
Main Study Screener
Completes, Main Study
Completes, Pretest
Pretest Screener

---

ICR Summary of Burden

table that charts list of burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	1,621	0	0	1,621	0	0
Annual Time Burden (Hours)	267	0	0	267	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to: Miscellaneous Actions

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement: This is a new data collection.

---

Annual Cost to Federal Government: $179,670

Does this IC contain surveys, censuses, or employ statistical methods? Yes Part B of Supporting Statement

Does this ICR request any personally identifiable information (see OMB Circular No. A-130 for an explanation of this term)? Please consult with your agency's privacy program when making this determination.     No

Does this ICR include a form that requires a Privacy Act Statement (see 5 U.S.C. §552a(e)(3))? Please consult with your agency's privacy program when making this determination.     No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 08/08/2019

---